Risankizumab shows benefits in psoriasis following suboptimal IL-17 treatment
Click Here to Manage Email Alerts
Key takeaways:
- 56.3% of patients treated with risankizumab after failing interleukin-17A treatments experienced clear or almost clear skin at week 12.
- By week 52, 63% reached a 0 or 1 static Physician Global Assessment score.
NEW ORLEANS — Patients with psoriasis who had suboptimal results with prior interleukin-17 therapy experienced beneficial results with risankizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.
“Within the real world, patients with residual disease really want to switch onto more effective therapy,” Richard B. Warren, MBChB, PhD, of the University of Manchester and Northern Care Alliance in the United Kingdom, told Healio. “This study had a pragmatic trial design without washout period and reassured there was no additional safety concern when switching to risankizumab (Skyrizi, AbbVie) after suboptimal response to secukinumab or ixekizumab.”
Warren presented 52-week data from a phase 3b open-label, single-arm study that included 250 patients with moderate to severe plaque psoriasis who had previously been treated with secukinumab or ixekizumab for at least 6 months and had a suboptimal response, defined as a static Physician Global Assessment (sPGA) score of 2 or 3 and a body surface area (BSA) of 3% to 10% affected.
Subjects received risankizumab 150 mg at weeks 0 and 4 and every 12 weeks for 1 year.
At week 16, 56.3% of patients achieved sPGA or 0 or 1, with 63% achieving that endpoint at week 52.
Completely clear skin, or sPGA 0, was achieved by 19.8% at week 16 and 26.2% at week 52.
Psoriasis Symptom Scale score of 0, meaning no pain, itching, redness or burning, was reported by 20.2% of patients at week 16 and 27.4% at week 52.
“In this study we have a clear definition of suboptimal response and know that patients are not fully controlled and as such may benefit from changing therapy,” Warren told Healio. “The impact of switching to risankizumab clearly demonstrated a significant proportion of patients benefit from making the switch after suboptimal response from the [interleukin]-17A therapies.”
No new safety signals were reported in this analysis. Of the study’s 250 subjects, 165 (65.5%) experienced at least one treatment emergent adverse event, with COVID-19 being the most common. Adjudicated major adverse cardiovascular events were reported in two subjects; however, the researchers reported these subjects had multiple cardiovascular risks.